Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1292263 alone and with atorvastatin in dyslipidemia
NCT01218204Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK-1292263 in dyslipidemia (16 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings and 7 more. Started Sep 2010; status: completed.
02
Drugs
GSK-1292263
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01218204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218204.